Self-collected Papanicolaou tests in the United States market: more questions than answers

Paul N. Staats, Christine N. Booth, Dorothy Rosenthal, Barbara A. Crothers

Research output: Contribution to journalReview article

Abstract

The United States Food and Drug Administration held a public hearing in January 2018 to consider how it should evaluate a self-collection device for cervical cytology. Although no such device has been approved for use in the US market, the implications for patients and cytologists could be both sweeping and complex. Herein, the existing literature basis for self-collected Papanicolaou testing is reviewed, and some questions raised by this testing are considered. Questions include: what would be the value to patients; how effective could self-collected Papanicolaou tests be; how might ordering and collection work; what are the unique pre-analytic, analytic, and post-analytic challenges of self-collected Papanicolaou testing; and what effect might self-collection have on cervical cancer rates?

Original languageEnglish (US)
JournalJournal of the American Society of Cytopathology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Papanicolaou Test
Equipment and Supplies
United States Food and Drug Administration
Uterine Cervical Neoplasms
Hearing
Cell Biology

Keywords

  • Cancer screening
  • Cervical cancer
  • Gynecologic cytology
  • Pap test
  • Papanicolaou test
  • Self-collection

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Self-collected Papanicolaou tests in the United States market : more questions than answers. / Staats, Paul N.; Booth, Christine N.; Rosenthal, Dorothy; Crothers, Barbara A.

In: Journal of the American Society of Cytopathology, 01.01.2019.

Research output: Contribution to journalReview article

@article{dc73de9041c74fac9498cb95870b39e1,
title = "Self-collected Papanicolaou tests in the United States market: more questions than answers",
abstract = "The United States Food and Drug Administration held a public hearing in January 2018 to consider how it should evaluate a self-collection device for cervical cytology. Although no such device has been approved for use in the US market, the implications for patients and cytologists could be both sweeping and complex. Herein, the existing literature basis for self-collected Papanicolaou testing is reviewed, and some questions raised by this testing are considered. Questions include: what would be the value to patients; how effective could self-collected Papanicolaou tests be; how might ordering and collection work; what are the unique pre-analytic, analytic, and post-analytic challenges of self-collected Papanicolaou testing; and what effect might self-collection have on cervical cancer rates?",
keywords = "Cancer screening, Cervical cancer, Gynecologic cytology, Pap test, Papanicolaou test, Self-collection",
author = "Staats, {Paul N.} and Booth, {Christine N.} and Dorothy Rosenthal and Crothers, {Barbara A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jasc.2019.05.003",
language = "English (US)",
journal = "Journal of the American Society of Cytopathology",
issn = "2213-2945",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Self-collected Papanicolaou tests in the United States market

T2 - more questions than answers

AU - Staats, Paul N.

AU - Booth, Christine N.

AU - Rosenthal, Dorothy

AU - Crothers, Barbara A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The United States Food and Drug Administration held a public hearing in January 2018 to consider how it should evaluate a self-collection device for cervical cytology. Although no such device has been approved for use in the US market, the implications for patients and cytologists could be both sweeping and complex. Herein, the existing literature basis for self-collected Papanicolaou testing is reviewed, and some questions raised by this testing are considered. Questions include: what would be the value to patients; how effective could self-collected Papanicolaou tests be; how might ordering and collection work; what are the unique pre-analytic, analytic, and post-analytic challenges of self-collected Papanicolaou testing; and what effect might self-collection have on cervical cancer rates?

AB - The United States Food and Drug Administration held a public hearing in January 2018 to consider how it should evaluate a self-collection device for cervical cytology. Although no such device has been approved for use in the US market, the implications for patients and cytologists could be both sweeping and complex. Herein, the existing literature basis for self-collected Papanicolaou testing is reviewed, and some questions raised by this testing are considered. Questions include: what would be the value to patients; how effective could self-collected Papanicolaou tests be; how might ordering and collection work; what are the unique pre-analytic, analytic, and post-analytic challenges of self-collected Papanicolaou testing; and what effect might self-collection have on cervical cancer rates?

KW - Cancer screening

KW - Cervical cancer

KW - Gynecologic cytology

KW - Pap test

KW - Papanicolaou test

KW - Self-collection

UR - http://www.scopus.com/inward/record.url?scp=85067933059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067933059&partnerID=8YFLogxK

U2 - 10.1016/j.jasc.2019.05.003

DO - 10.1016/j.jasc.2019.05.003

M3 - Review article

C2 - 31257176

AN - SCOPUS:85067933059

JO - Journal of the American Society of Cytopathology

JF - Journal of the American Society of Cytopathology

SN - 2213-2945

ER -